Content area

|
|

Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

Et superficielt spredende melanom.
Forfatter(e)
Tessa Bystrup Boyles1, Inge Marie Svane2, Lars Bastholt3 & Henrik Schmidt1 1) Onkologisk Afdeling, Aarhus Universitetshospital 2) Center for Cancer og Immunterapi, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2016;178:V02160126
Reference: 
Ugeskr Læger 2016;178:V02160126
Blad nummer: 
Sidetal: 
2-5
Treatment of BRAF-mutated metastatic melanoma
Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was con­sidered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the com­bi­n­ation of the inhibitors, many patients develop acquired resistance within a year.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Christen Ravn | 13/06
4 kommentarer
af Rasmus Philip Nielsen | 13/06
2 kommentarer
af Carsten Reidies Bjarkam | 10/06
1 Kommentar
af Inger Ros | 08/06
4 kommentarer
af Birger Kreutzfeldt | 08/06
1 Kommentar
af Leo Kirkegaard Winther | 07/06
1 Kommentar
af Andreas Sven Lennart Saine Granlund | 07/06
1 Kommentar